GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects
Aging · 2024
DOI: 10.18632/aging.205489 ↗At a glance
Journal article in Aging, 2024. Written by Hyun-Hee Park and 9 co-authors. Institution: Department of Neurology, Hanyang University Guri Hospital, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, Korea. Major MEDLINE topics: Telomerase, Alzheimer Disease. Cited 1 times so far (Crossref); 59 references. The full text is freely available in PubMed Central. Funded by: NIEHS NIH HHS.
Abstract (original language)
GV1001, which mimics the activity of human telomerase reverse transcriptase, protects neural cells from amyloid beta (Aβ) toxicity and other stressors through extra-telomeric function, as noted in our prior in vitro studies. As per a recent phase II clinical trial, it improves cognitive function in patients with moderate to severe dementia. However, the underlying protective mechanisms remain unclear. This study aimed to investigate the effects of GV1001 on neurodegeneration, senescence, and survival in triple transgenic Alzheimer's disease (3xTg-AD) mice. GV1001 (1 mg/kg) was subcutaneously injected into old 3xTg-AD mice thrice a week until the endpoint for sacrifice, and survival was analysed. Magnetic resonance imaging (MRI) and Prussian blue staining (PBS) were performed to evaluate entry of GV1001 entrance into the brain. Diverse molecular studies were performed to investigate the effect of GV1001 on neurodegeneration and cellular senescence in AD model mice, with a particular focus on BACE, amyloid beta1-42 (Aβ1-42), phosphorylated tau, volume of dentate gyrus, β-galactosidase positive cells, telomere length, telomerase activity, and ageing-associated proteins. GV1001 crossed the blood-brain barrier, as confirmed by assessing the status of ferrocenecarboxylic acid-conjugated GV1001 using magnetic resonance imaging and PBS. GV1001 increased the survival of 3xTg-AD mice. It decreased BACE and Aβ1-42 levels, neurodegeneration (i.e., reduced CA1, CA3 and dentate gyrus volume, decreased levels of senescence-associated β-galactosidase positive cells, and increased telomere length and telomerase activity), and levels of ageing-associated proteins. We suggest that GV1001 exerts anti-ageing effects in 3xTg-AD mice by reducing neurodegeneration and senescence, which contributes to improved survival.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, Hanyang University Guri Hospital, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, Korea.
- Department of Neurosurgery, Hanyang University Guri Hospital, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, Korea.
- Department of Radiology, Hanyang University Guri Hospital, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, Korea.
- Teloid Inc., Los Angeles, CA 90010, USA.
- Department of Translational Medicine, Hanyang University Graduate School of Biomedical Science and Engineering, Seoul 04763, Korea.
Funding
- NIEHS NIH HHS
Cite
APA
Park, H. H., Kwon, H. S., Lee, K. Y., Kim, Y. E., Son, J. W., Choi, N. Y., Han, M. H., Park, D. W., Kim, S., & Koh, S. H. (2024). GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects. Aging. https://doi.org/10.18632/aging.205489
Vancouver
Park HH, Kwon HS, Lee KY, Kim YE, Son JW, Choi NY, et al. GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects. Aging. 2024. doi:10.18632/aging.205489
BibTeX
@article{Park2024,
author = {Park, Hyun-Hee and Kwon, Hyuk Sung and Lee, Kyu-Yong and Kim, Ye Eun and Son, Jeong-Woo and Choi, Na-Young and Han, Myung-Hoon and Park, Dong Woo and Kim, Sangjae and Koh, Seong-Ho},
title = {GV1001 reduces neurodegeneration and prolongs lifespan in 3xTg-AD mouse model through anti-aging effects},
journal = {Aging},
year = {2024},
doi = {10.18632/aging.205489}
}
EUVIMED